Truist raised the firm’s price target on Fulcrum Therapeutics (FULC) to $18 from $14 and keeps a Buy rating on the shares. Positive reception is persisting around the cohort 4 data from the phase 1b PIONEER study for pociredir in sickle cell disease, SCD, which came in as a win for the company, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics Announces $175 Million Public Offering
- Fulcrum Therapeutics 11.85M share Secondary priced at $13.50
- Fulcrum Therapeutics price target raised to $7 from $6 at BofA
- Cautious Outlook for Fulcrum Therapeutics Amidst PIONEER Study Challenges and Market Uncertainties
- Fulcrum Therapeutics announces $150M offering of common stock